Jens Hoffmann, PhD

Experimental Pharmacology & Oncology Berlin-Buch GmbH (EPO), Berlin, Germany.

Dr Hoffmann is the CEO of Experimental Pharmacology & Oncology Berlin-Buch GmbH (EPO), one of Germanys leading contract research organization (CRO) that provides comprehensive services for preclinical oncology research. He has specialized in preclinical and translational research to support drug development, starting from target validation and compound screening, and ending with integrational in vivo studies addressing pharmacology, pharmacokinetics, biomarkers, and tolerability. He is developing personalized models for tumor profiling to support the selection of the most appropriate drug treatment for the individual cancer patient. Dr. Hoffmann has a long standing expertise for pharmacological investigations concerning endocrine tumors.

Dr. Hoffmann studied pharmacy at the University of Greifswald and obtained a Diploma in Pharmacy and Experimental Pharmacology and Toxicology and the PhD degree from the Humboldt University Berlin on “Investigations on the phenomenon of multidrug resistance, markers of resistance, and correlation with clinical outcome”. He took postdoc positions at Schering AG in the Experimental Oncology working on tumor angiogenesis and at the University of Pittsburgh, School of Medicine, Department of Pharmacology on “Redox regulation and cell death”.

From 1997 to 2009 he worked as group leader in Oncology Research at the Schering AG and Bayer Pharma AG. His main research field was the development of novel steroid hormone receptor antagonists and mechanisms of antihormone resistance. He worked on the preclinical development of new cancer drugs, translational research, and small animal imaging. For that purpose, he developed several new in vivo models, especially for tumor angiogenesis, sarcomas, and hormone dependent cancers.

Dr. Hoffmann is member of the German Cancer Foundation and the Board of the Experimental Cancer Research Division (AEK) and the American Association for Cancer Research (AACR). He is guest scientist at the Comprehensive Cancer Center of the Charite Berlin, member of the CONELIS expert network and of the board of CPO Cellular Phenomics and Oncology.

He has published more than 50 original articles in peer reviewed journals and filed more than 30 patents.